Back to top

Analyst Blog

This page is temporarily not available.  Please check later as it should be available shortly. If you have any questions, please email customer support at support@zacks.com or call 800-767-3771 ext.  9339.

Shares of Affymetrix Inc.’s (AFFX - Analyst Report) rose 6.4% to $5.00 yesterday following the release of its promising 2013-second quarter results on Jul 31. The company reported its first earnings since the first quarter of 2011. The stock price is very close to the 52-week high of $5.26 on Jul 12.

Affymetrix posted adjusted earnings per share of 4 cents in the quarter in sharp contrast to the year-ago adjusted loss of 13 cents. This reflected a whopping 500% earnings surprise compared with the Zacks Consensus Estimate of a loss of a penny.

Thanks to AFFX’s strategic restructuring plans and its acquisition of eBioscience in Jun 2012 that has opened new avenues for the company and turned its focus away from the beleaguered Gene Expression business.

Revenues increased 19.7% year over year to $79.5 million (including the eBioscience acquisition), almost in line with the Zacks Consensus Estimate. eBioscience revenues increased manifold to $18.8 million from $1.4 million in the year-ago period.

During the quarter, Affymetrix launched a new product, Axiom 384HT Genotyping Format, a high-throughput platform capable of genotyping 384 samples simultaneously and run on the GeneTitan Instrument.

We are impressed with Affymetrix’s strong second-quarter results, following a dismal first quarter. We believe that AFFX is ready for a turnaround due to management's strategy to transform it into a company with a broad reach in the high-growth markets for translational medicine, molecular diagnostics and applied markets. Despite a tight U.S. academic funding environment, AFFX’s new products and strategic agreements should propel growth in the company.

Currently, AFFX has a Zacks Rank #1 (Strong Buy). Other companies like Biogen Idec (BIIB - Analyst Report), Gilead Sciences (GILD - Analyst Report) and Actelion (ALIOF), all carrying a Zacks Rank #1 (Strong Buy), are also expected to do well in the Medical-Biomed/Gene industry.

Please login to Zacks.com or register to post a comment.

New to Zacks?

Start Here

Zacks Investment Research

Close

Are you a new Zacks Member or a visitor to Zacks.com?

Top Zacks Features

Learn more

Start for as little as $4.50 per trade.

My Portfolio Tracker

Is it Time to Sell?

One of the most important steps you can take today is to set up your portfolio tracker on Zacks.com. Once you do, you'll be notified of major events affecting your stocks and/or funds with daily email alerts.

More Zacks Resources

Zacks Rank Home - Evaluate your stocks and use the Zacks Rank to eliminate the losers and keep the winners.

Mutual Fund Rank Home - Evaluate your funds with the Mutual Fund Rank for both your personal and retirement funds.

Stock/Mutual Fund Screening - Find better stocks and mutual funds. The ones most likely to beat the market and provide a positive return.

My Portfolio - Track your Portfolio and find out where your stocks/mutual funds stack up with the Zacks Rank.

Zacks #1 Rank Top Movers for Zacks #1 Rank Top Movers

Company Symbol Price %Chg
BITAUTO HOLD BITA 35.28 +14.66%
ANI PHARMACE ANIP 24.64 +13.97%
E HOUSECHINA EJ 11.01 +9.44%
CANADIAN SOL CSIQ 26.90 +6.87%
KNIGHTSBRIDG VLCCF 12.47 +5.50%